Director Howard Ian Sudnow filed an initial statement of beneficial ownership with the SEC on November 6, 2026, disclosing no securities held in Sunrise Realty Trust, Inc. as of the event date of November 5, 2026.
Director Howard Ian Sudnow filed a Form 4 with the SEC on November 6, 2026, reporting the acquisition of 1,500 shares of Sunrise Realty Trust, Inc. common stock on November 5, 2026, received upon completion of a merger involving Southern Realty Trust Inc.
Roku, LLC, as successor by merger to Roku, Inc., filed nine post-effective amendments on November 6, 2026, to deregister all unsold shares of Common Stock previously registered under nine Form S-8 registration statements covering employee equity and benefit plans.
Michael J. Wartell filed an initial statement of beneficial ownership (Form 3) with the SEC on November 6, 2026, disclosing his status as a newly appointed director of Fractyl Health, Inc. as of November 2, 2026.
Delta Air Lines President Peter W. Carter filed a Form 4 on November 6, 2026, disclosing the sale of 44,950 shares of Delta Air Lines common stock on November 4, 2026.
Kontoor Brands, Inc. filed a Form 8-K on November 6, 2026, disclosing the completed sale of its wholly-owned subsidiary The H.D. Lee Company, Inc. to ABG-Storm LLC, an affiliate of Authentic Brands Group, on November 2, 2026.
Alclear Investments, LLC filed a Form 4 with the SEC on November 6, 2026, disclosing the sale of 176,096 shares of Clear Secure, Inc. Class A Common Stock on November 4, 2026, executed pursuant to a Rule 10b5-1 trading plan.
Caryn Seidman Becker, Chief Executive Officer and 10% owner of Clear Secure, Inc. (NYSE:YOU), filed a Form 4 on November 6, 2026, disclosing the sale of 176,096 shares of Class A Common Stock on November 4, 2026, along with related unit exchanges completed on …
Daniel Patrick O'Day, Chairman and CEO of Gilead Sciences, Inc., filed a Form 4 on November 6, 2026, disclosing the exercise of non-qualified stock options and sale of common stock on November 4 and November 5, 2026, pursuant to a Rule 10b5-1 trading plan.
Shannon T Kelley, General Counsel of Madrigal Pharmaceuticals, Inc., filed a Form 4 on November 6, 2026, disclosing the sale of 1,077 shares of common stock at $400 per share under a pre-established Rule 10b5-1 trading plan.